Abstracts tagged "Systemic sclerosis"

Abstract Number: 2033 • ACR Convergence 2020
Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
Brian Skaug¹, Marka Lyons¹, William Swindell², Gloria Salazar¹, Julio Charles¹, Connor Vershel¹, Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²The Jewish Hospital, Department of Internal Medicine, Cincinnati, OH, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Numerous studies have revealed dysregulated gene expression in the skin of systemic sclerosis (SSc) patients, with varying degrees of inflammatory/immune and fibroblast upregulation. However,…
Abstract Number: 0388 • ACR Convergence 2020
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
Masataka Kuwana¹, Shervin Assassi², Jérôme Avouac³, Rachel Hoyles⁴, Janet Pope⁵, Vanessa Smith⁶, Corinna Miede⁷, Emmanuelle Clerisme-Beaty⁸, Margarida Alves⁹ and Oliver Distler¹⁰, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ²University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ³Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris Descartes University, France, Paris, France, ⁴Department of Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ⁷mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim, Germany, Ingelheim, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁰Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The progression of SSc-ILD is variable and unpredictable. However, observational studies have identified patient characteristics that may be prognostic of a greater rate of…
Abstract Number: 0925 • ACR Convergence 2020
Early Hydroxychloroquine Use May Reduce Risk for SSc-Associated Pulmonary Hypertension
Alexandra Boucher¹, Yongseok Park², Shannon Zalewski³, Maureen Laffoon², Thomas Medsger⁴, Robert Lafyatis² and Robyn Domsic⁵, ¹University of Pittsburgh, Camp Hill, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Washington University Barnes Jewish Hospital, Saint Louis, MO, ⁴University of Pittsburgh School of Medicine, Verona, PA, ⁵University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) patients are at high risk for pulmonary hypertension (PH), a leading cause of death in this population. Chloroquine is a pulmonary…
Abstract Number: 1388 • ACR Convergence 2020
A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Elizabeth Volkmann³, Laura Hummers⁴, Fredrick Wigley⁵ and Zsuzsanna McMahan⁶, ¹JHUSOM, Baltimore, ²JHUSPH, Baltimore, ³University of California, Los Angeles, Los Angeles, CA, ⁴Johns Hopkins Univerisity, Ellicott City, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University, Baltimore
Background/Purpose: Colonic dysmotility affects up to 50% of patients with systemic sclerosis (SSc). While some patients have mild colonic disease, others experience severe complications, such…
Abstract Number: 2035 • ACR Convergence 2020
Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design
Robyn Domsic¹, Shiyao Gao², Maureen Laffoon², Steven Wisniewski³, Robert Lafyatis⁴, Virginia Steen⁵ and Thomas Medsger⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Arlington, MA, ⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁶University of Pittsburgh School of Medicine, Verona, PA
Background/Purpose: Clinical trials in early diffuse systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome have been largely negative. This…
Abstract Number: 0389 • ACR Convergence 2020
Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Patients with Systemic Sclerosis
Kyle Kidwell¹, Leslie J. Crofford¹ and April Barnado¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Assembling large cohorts of patients with rare diseases is difficult and limits the power to assess outcomes in systemic sclerosis (SSc) studies. Treatment in…
Abstract Number: 0930 • ACR Convergence 2020
Sexual Health Impairment in 90 Female Patients with Systemic Sclerosis
Barbora Hermankova¹, Maja Spiritovic², Sabina Oreska³, Hana Storkanova⁴, Hana Smucrova⁵, Karel Pavelka⁶, Jiří Vencovský⁶, Ladislav Šenolt⁶, Radim Becvar⁴ and Michal Tomcik⁴, ¹Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Hlavni mesto Praha, Czech Republic, ²Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is a chronic, multisystem, connective tissue disorder characterized by fibrosis of the skin and internal organ involvement. These serious clinical manifestations…
Abstract Number: 1391 • ACR Convergence 2020
Associations Between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry
Selma Lazizi¹, Marie Hudson², Murray Baron³, Marvin Fritzler⁴ and Sabrina Hoa⁵, ¹Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Jewish General Hospital, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Autoantibodies are useful in systemic sclerosis (SSc) for predicting disease course. Some autoantibodies have been associated with a close temporal relationship with cancer. We…
Abstract Number: 2037 • ACR Convergence 2020
Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts
Anastasiya Muntyanu¹, Bina Kassamali², Ruth Ann Vleugels³ and Avery LaChance³, ¹McGill University, Montreal, QC, Canada, ²Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune sclerosing disease with a 10-year survival rate of less than 65%. This rate has remained unchanged for…
Abstract Number: 720 • 2019 ACR/ARP Annual Meeting
Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Robert Spiera¹, Nancy Dgetluck ², Bradley Bloom ², Barbara White ² and Christopher Denton ³, ¹Hospital for Special Surgery, New York, NY, ²Corbus Pharmaceuticals, Norwood, MA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: We report the baseline characteristics of a large cohort of diffuse cutaneous systemic sclerosis (dcSSc) patients enrolled in a Phase 3 trial of lenabasum,…
Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Mark Nicolls¹, David Badesch ², Lorinda Chung ³, Robyn Domsic ⁴, Thomas Medsger ⁵, Ashley Pinckney ⁶, Lynette Keyes-Elstein ⁶, Carla D'Aveta ⁶, Meagan Spychala ⁶, R James White ⁷, Paul Hassoun ⁸, Fernando Torres ⁹, Jerry Molitor ¹⁰, Dinesh Khanna ¹¹, Holden Maeker ¹², Beverly Welch ¹³, Ellen Goldmuntz ¹⁴, Roham Zamanian ¹ and -- On Behalf of ASC01 Investigators ¹⁵, ¹Stanford University, Stanford, ²University of Colorado, Denver, ³Stanford University, Palo Alto, CA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, ⁶Rho Federal Systems, Durham, ⁷University of Rochester, Rochester, NY, ⁸Johns Hopkins School of Medicine, Baltimore, ⁹UT Southwestern, Dallas, ¹⁰University of Minnesota, University of Minnesota, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²Stanford, Stanford, ¹³National Institute of Allergy and Infectious Diseases, NIH, Bethesda, ¹⁴NIAID, Washingto, DC, ¹⁵---, USA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…
Abstract Number: 1068 • 2019 ACR/ARP Annual Meeting
Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures
Paula Ramos¹, Willian da Silveira ², Jena Wirth ¹, Nathan Wilson ¹, Robert Wilson ¹, Jin Hyun Nam ¹, E. Starr Hazard ¹, Jim Oates ³, Melissa Cunningham ¹, Dongjun Chung ¹ and Gary Hardiman ², ¹Medical University of South Carolina, Charleston, ²Queen’s University, Belfast, United Kingdom, ³Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disorder characterized by immune dysregulation, cutaneous and visceral fibrosis, and vasculopathy. It disproportionately affects African ancestry (AA)…
Abstract Number: 1651 • 2019 ACR/ARP Annual Meeting
Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers
Vivek Nagaraja¹, Cathie Spino ¹, Pei-Suen Tsou ¹, Robyn Domsic ², Robert Lafyatis ², Tracy Frech ³, Jessica Gordon ⁴, Virginia Steen ⁵ and Dinesh Khanna ⁶, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ⁴Hospital for Special Surgery, New York, NY, ⁵Georgetown University, Washington, D.C., USA, Georgetown, ⁶Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: The soluble guanylate cyclase stimulator riociguat (RIO) is a vasodilator with efficacy in patients with pulmonary arterial hypertension associated with connective tissue disease. Our…
Abstract Number: 2592 • 2019 ACR/ARP Annual Meeting
Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care
Nancy Maltez¹, Mathieu Puyade ², Pauline Lansiaux ³, Mianbo Wang ⁴, Murray Baron ⁵, Ines Colmegna ⁶, Dominique Farge ⁷ and Marie Hudson ⁸, ¹The Ottawa Hospital, Ottawa, ²CHU de Poitiers Unité d'Hospitalisation d'Aval, Poitiers Cédex, France, ³Institut de Recherche Saint-Louis, Paris, France, ⁴Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ⁵Jewish General Hospital, McGill University, Montreal, Canada, ⁶McGill University Health Center, Montreal, QC, Canada, ⁷Hôpital Saint-Louis, AP-HP Assistance Publique des Hôpitaux de Paris, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d’Ile-de-France, Filière ‘FAI2R’, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Université de Paris, EA 3518, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada, Paris, France, ⁸Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: In severe, early progressive systemic sclerosis (SSc), autologous hematopoietic stem cell transplantation (AHSCT) allows significant improvements in overall and event free survival. The objectives…
Abstract Number: 2612 • 2019 ACR/ARP Annual Meeting
Minocycline for Refractory Calcinosis in Systemic Sclerosis: A Single-Centre Observational Cohort Study
Carmen Fonseca¹, Voon Ong ² and Christopher Denton ³, ¹UCL Medical School, Royal Free Campus, London, United Kingdom, ²UCL Medical School, Royal Free Campus, London, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Calcinosis represents a major challenge for patients with systemic sclerosis (SSc) for which there is no standard therapy. Minocycline has been proposed for treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].